Hillsdale Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hillsdale Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-153,728	Closed	-$2.82M	–	594
2024 Q4	$2.82M	Buy	153,728 +100	+0.1%	+$1.61K	0.14%	189
2024 Q3	$2.36M	Buy	153,628 +1,100	+0.7%	+$18.4K	0.18%	187
2024 Q2	$2.48M	Sell	152,528 -5,160	-3%	-$83.3K	0.2%	180
2024 Q1	$2.92M	Buy	157,688 +12,530	+9%	+$310K	0.23%	166
2023 Q4	$4.54M	Buy	145,158 +11,340	+8%	+$271K	0.37%	76
2023 Q3	$2.79M	Buy	133,818 +22,690	+20%	+$616K	0.26%	148
2023 Q2	$2.66M	Buy	+111,128	New	+$2.47M	0.24%	150
2020 Q3	–	Sell	-16,400	Closed	-$795K	–	567
2020 Q2	$795K	Sell	16,400 -1,000	-6%	-$48K	0.07%	218
2020 Q1	$735K	Sell	17,400 -1,500	-8%	-$61.8K	0.09%	194
2019 Q4	$809K	Buy	+18,900	New	+$822K	0.07%	264

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Hillsdale Investment Management's ACAD Position: Q1 2025 in Review

Hillsdale Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 153,728 shares — an estimated $2.82M sold.

Hillsdale Investment Management first reported a position in ACAD in Q4 2019 and held it in 10 quarters. The position peaked at $4.54M in Q4 2023. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Hillsdale Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Hillsdale Investment Management sold 153,728 Acadia Pharmaceuticals shares in Q1 2025, an estimated $2.82M.
Hillsdale Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Hillsdale Investment Management's Acadia Pharmaceuticals position peaked at $4.54M in Q4 2023.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Hillsdale Investment Management's 13F filing for Q1 2025, filed 9 May 2025.